BCL2 and cancer: Assuming that the abundance of anti-apoptotic BCL-2 proteins in TIS cells and the dynamic evolution of the BCL-2/BH3 interactome at the mitochondria are critical to determining heterogeneous responses to BH3 senolytic drugs, the researchers used different versions of the so-called BH3 profiling to predict TIS cancer cell sensitivity to these drugs.